Finerenone in Type 1 Diabetes and Chronic Kidney Disease.
Summary
In this phase 3 randomized trial in adults with type 1 diabetes and CKD, finerenone produced a 25% greater reduction in urinary albumin-to-creatinine ratio over 6 months versus placebo. Hyperkalemia was more frequent with finerenone but rarely led to discontinuation.
Key Findings
- Finerenone reduced urinary albumin-to-creatinine ratio by 34% over 6 months versus 12% with placebo.
- Geometric mean ratio for finerenone vs placebo was 0.75 (95% CI, 0.65–0.87; P<0.001), indicating a 25% greater reduction.
- Hyperkalemia occurred in 10.1% with finerenone vs 3.3% with placebo; 1.7% discontinued due to hyperkalemia.
Clinical Implications
Finerenone may become a therapeutic option to reduce albuminuria in type 1 diabetes with CKD, with monitoring for hyperkalemia. Outcomes trials are needed to confirm effects on hard renal and cardiovascular endpoints.
Why It Matters
This is the first phase 3 RCT to demonstrate albuminuria lowering with finerenone in type 1 diabetes CKD, extending benefits beyond type 2 diabetes and informing cardio-renal risk reduction strategies.
Limitations
- Short follow-up (6 months) and surrogate primary endpoint (albuminuria) rather than hard outcomes
- Modest sample size may limit power for safety and subgroup analyses
Future Directions
Larger, longer-term trials in type 1 diabetes should evaluate renal and cardiovascular outcomes, optimal monitoring strategies for hyperkalemia, and integration with existing RAAS blockade and SGLT2 inhibitors.
Study Information
- Study Type
- RCT
- Research Domain
- Treatment
- Evidence Level
- I - High-quality randomized controlled trial evidence
- Study Design
- OTHER